Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Calmy

Showing results (391-400 of 415) with videos related to

Pageof 42
Sort By:
The Lancet Regional Health. Europe|January 1, 2024
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandPaul Thoueille, Susana Alves Saldanha, Fabian Schaller, et al.
AIDS (London, England)|November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaEmmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
Eclinicalmedicine|November 15, 2021
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialNiklaus D Labhardt, Mikaela Smit, Ianis Petignat, et al.
Nature Medicine|November 8, 2016
Determinants of HIV-1 broadly neutralizing antibody inductionPeter Rusert, Roger D Kouyos, Claus Kadelka, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
BMJ Open|November 22, 2024
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trialMarie Ballif, Dominique Braun, Alexandra Calmy, et al.
The Journal of Infectious Diseases|January 16, 2024
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyIrene A Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
AIDS (London, England)|April 10, 2026
Improving cohort coverage estimation using a data triangulation framework: the Swiss HIV Cohort Study exampleJessy J Duran Ramirez, Roger D Kouyos, Irene Abela, et al.
Journal of Clinical Epidemiology|September 14, 2025
Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods studyElias R Zehnder, Christof Manuel Schönenberger, Julia Hüllstrung, et al.
Journal of Clinical Epidemiology|November 21, 2025
Corrigendum to 'Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods study' [Journal of Clinical Epidemiology, 188 (2025) 111973]Elias R Zehnder, Christof Manuel Schönenberger, Julia Hüllstrung, et al.
Pageof 42

Showing results (391-400 of 415) with videos related to

Sort By:
Pageof 42
The Lancet Regional Health. Europe|January 1, 2024
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandPaul Thoueille, Susana Alves Saldanha, Fabian Schaller, et al.
AIDS (London, England)|November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaEmmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
Eclinicalmedicine|November 15, 2021
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialNiklaus D Labhardt, Mikaela Smit, Ianis Petignat, et al.
Nature Medicine|November 8, 2016
Determinants of HIV-1 broadly neutralizing antibody inductionPeter Rusert, Roger D Kouyos, Claus Kadelka, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
BMJ Open|November 22, 2024
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trialMarie Ballif, Dominique Braun, Alexandra Calmy, et al.
The Journal of Infectious Diseases|January 16, 2024
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyIrene A Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
AIDS (London, England)|April 10, 2026
Improving cohort coverage estimation using a data triangulation framework: the Swiss HIV Cohort Study exampleJessy J Duran Ramirez, Roger D Kouyos, Irene Abela, et al.
Journal of Clinical Epidemiology|September 14, 2025
Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods studyElias R Zehnder, Christof Manuel Schönenberger, Julia Hüllstrung, et al.
Journal of Clinical Epidemiology|November 21, 2025
Corrigendum to 'Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods study' [Journal of Clinical Epidemiology, 188 (2025) 111973]Elias R Zehnder, Christof Manuel Schönenberger, Julia Hüllstrung, et al.
Pageof 42